Kelly Clark
Adult Health · Michigan City, INNPI 1811086903
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.1% of the total across 179 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,192, 8.6 times the $138 reported in 2021.
Across 179 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$690
- Teva Pharmaceuticals USA, Inc.$500
- Neurocrine Biosciences, Inc.$448
- Alkermes, Inc.$398
- Johnson & Johnson$346
- Lundbeck LLC$244
- plus $897 from 9 others
What the payments were for
- Food & beverage$3,17290%
- Education$35010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $690 |
| Teva Pharmaceuticals USA, Inc. | 18 | $500 |
| Neurocrine Biosciences, Inc. | 25 | $448 |
| Alkermes, Inc. | 21 | $398 |
| Johnson & Johnson | 17 | $346 |
| Lundbeck LLC | 14 | $244 |
| E.r. Squibb & Sons, L.L.C. | 20 | $237 |
| Otsuka America Pharmaceutical, Inc. | 11 | $187 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $168 |
| Vanda Pharmaceuticals Inc. | 4 | $127 |
| Sunovion Pharmaceuticals Inc. | 3 | $72 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Indivior Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
How this compares
$3,522 in reported general payments places this provider in the 85th percentile of 391 adult health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 95 | $309,976 |
| IngrezzaValbenazine Tosylate | 39 | $297,227 |
| AustedoDeutetrabenazine | 42 | $273,622 |
| VraylarCariprazine Hcl | 60 | $95,418 |
| RexultiBrexpiprazole | 61 | $85,835 |
| Lurasidone Hcl | 92 | $45,032 |
| TrintellixVortioxetine Hydrobromide | 88 | $40,418 |
| CaplytaLumateperone Tosylate | 24 | $36,820 |
| Chlorpromazine Hcl | 56 | $35,855 |
| Abilify MaintenaAripiprazole | 12 | $33,387 |
| AristadaAripiprazole Lauroxil | 13 | $30,862 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $21,258 |
| Oxcarbazepine | 263 | $20,598 |
| Paliperidone ErPaliperidone | 72 | $20,540 |
| Aripiprazole | 207 | $18,845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $346 | $309,97695 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $448 | $297,22739 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $500 | $273,62242 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $187 | $119,22273 claims |
| AbbVieVraylar | $690 | $95,41860 claims |
| Alkermes, Inc.Aristada, Lybalvi | $398 | $52,12027 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $27 | $47,290108 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $168 | $36,82024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 391 adult health providers in Indiana.
Other adult health in Michigan City
- Jennifer BerryIndianapolis$50K
- Tajuana DavisZionsville$31K
- Patricia Damron-RobinsonMerrillville$20K
- Terry RidgeCarmel$20K
- Kristine StarcevichMerrillville$19K
- Jolyn Holliday VezaGreenfield$17K
- Anna MatulewiczMishawaka$14K
- Ludmila Pichugena-EmersonMiddlebury$14K
- Vincent SmithMerrillville$13K
- Lisa DankoCrown Point$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.